Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitleINMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.AuthorsHübel, K.; Scholz, C. W.; Luminari, S.; Salar, A.; Wahlin, B. E.; Gopal, A. K.; Bonnet, C.; Trneny, M.; Paneesha, S.; Manzke, O.; Seguy, F.; Li, D.; Sehn, L. H.PublicationHematological Oncology, 2021, Vol 39, p1ISSN0278-0232Publication typeArticleDOI10.1002/hon.175_2880